Research Progress of Fusion Genes RET in Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2021.102.22
- Author:
Yujun ZHENG
1
;
Wei JIANG
1
;
Dongyan CHEN
1
;
Yanjun LI
1
;
Lulu DAI
1
;
Lei HUANG
1
;
Mingji WANG
1
Author Information
1. Department of Oncology, The Friendship Hospital of Dalian, Dalian 116001, China.
- Publication Type:Journal Article
- Keywords:
Fusion gene;
Lung neoplasms;
Transfection proto-oncogene gene
- From:
Chinese Journal of Lung Cancer
2021;24(8):591-597
- CountryChina
- Language:Chinese
-
Abstract:
In the past 20 years, with the development of molecular biology, the treatment of non-small cell lung cancer (NSCLC) has been developing. Targeted therapy has improved the survival period of patients with positive mutation of tumor driver gene. More and more targets have been found gradually. Drugs targeting different driving genes have brought the treatment of NSCLC into a promising target era. Among the many driving genes of NSCLC, the fusion of transfection proto oncogene (RET) is the addition of the epidermal growth factor receptor (EGFR), analytic lymphama kinase (ALK) and c-ros oncogene 1-receptor tyrosine kinase (ROS1) are emerging targets. Targeted drugs for RET gene fusion have been constantly updated. Recently, new high selective RET inhibitors blu-667 and loxo-292 have made important breakthroughs. This paper will review the review of the fusion mutation of RET gene in NSCLC, the detection methods, clinicopathological characteristics, targeted treatment and the research progress after drug resistance.
.
